| This week's sponsor is FierceBiotech Drug Development Forum. | |  | FierceBiotech 2nd Drug Development Forum - September 25-27 in Boston
90+ executive-level speakers share advanced partnership and pipeline strategies. Learn to adapt to increased deal complexity, real world evidence and digital technologies. Unequaled networking! Sign up by August 11 to save $200 on registration. |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Wednesday, July 26, 2017 GlaxoSmithKline is scrapping more than 30 drug development programs. The major cull of pipeline prospects will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space. |
|
|
| This week's sponsor is DocuSign. | |  | Whitepaper DocuSign and 21 CFR Part 11
Paperless. It is the nirvana that Life Sciences organizations have been chasing for the past 30 years. The time is finally now. A digital transformation is taking place in the life sciences industry, from research laboratories to manufacturing facilities. Read more. |
Top Stories Of The Week Monday, July 24, 2017 GlaxoSmithKline employees are going to need courage to work for new CEO Emma Walmsley. In fact, courage is one of the criteria that employees will be measured on going forward as Walmsley impresses her own style on employees. Thursday, July 27, 2017 One of AstraZeneca’s big hopes has missed a key primary endpoint in first-line lung cancer patients. Thursday, July 27, 2017 Will Mystic make it? That’s been the pressing question for AstraZeneca for months as the lung cancer trial proceeded. Answer: It didn’t, at least not yet. And it’s not just AZ's rep riding on that news, because Mystic was seen as a scrying glass of sorts. It would foretell which cancer cocktails would dominate over the next few years. Tuesday, July 25, 2017 Eli Lilly is seeking partners for two-thirds of its midphase oncology compounds. The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to midstage assets it thinks can become the new standard of care. Friday, July 21, 2017 Cyndi Lauper is back to star in another round of Novartis’ psoriasis marketing. The '80s pop music icon, who last year partnered with the Swiss pharma giant and the National Psoriasis Foundation on a disease-awareness push, appears with two real-life patients in Novartis’ newest Cosentyx spot. Monday, July 24, 2017 Penn scientists have spent the last two years exploring the potential of chimeric antigen receptor T (CAR-T) cell therapy in glioblastoma. A new study suggests a multipronged immune attack may be needed to fight this type of brain tumor. Tuesday, July 25, 2017 The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—a goal its closest rival, Bristol-Myers' Opdivo, met last year. It's the latest in a series of differing I-O results that highlight how much we still don’t know about these big-selling—and groundbreaking—therapies. Friday, July 21, 2017 U.S. manufacturer Corning said it is time the pharmaceutical industry has new, more durable glass for its new injected medicines, and with input and commitments from Pfizer and Merck & Co., it intends to produce it in the U.S. Friday, July 21, 2017 After outsourcing most of its clinical development efforts to PRA Health Sciences, Takeda is once again seeking outside help, this time in the upper stream, forming a multiyear R&D collaboration with in silico drug discovery expert Schrödinger. Monday, July 24, 2017 The decadeslong quest for a successful HIV vaccine has yielded plenty of failures, but with new early-stage results announced Monday, Johnson & Johnson and its partners hope they might have a winner that can work against viral subtypes worldwide. Wednesday, July 26, 2017 Verily has built a lab on its South San Francisco campus for cancer-testing startup Freenome, CNBC reports. The subsidiary of Google’s parent company designed the lab to Freenome’s specifications to foster collaboration after quietly participating in its $65 million financing round in March. |
|
